We discuss the new recommendations of the European Society of Clinical Oncology on the management of venous thromboembolism in oncology patients with Prof. Lucjan Wyrwicz of the Department of Oncology and Radiotherapy at the National Cancer Institute, National Research Institute in Warsaw.
Medexpress: Thromboembolic incidents - how significant is this problem in cancer patients?
L.W.: This is a problem that has long been known to be important. As early as the 19th century, syndromes associated with thromboembolic disorders in cancer patients were described. Since then, our knowledge has expanded greatly. Medications have long since appeared, which we use both for prevention and treatment. Today we are talking because there are new recommendations from the European Society of Clinical Oncology (ESMO) for the management of these conditions. And this is very important, because the ESMO recommendations raise the profile of the problem of thromboembolic disorders in oncology.
Medexpress: What do the new ESMO recommendations bring?
L.W.: We ha...